

COMPANY OVERVIEW

Advaxis, Inc. is a late-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis' investigational immunotherapies are designed to capitalize on the body's ability to recognize and attack bacterial infections. Our proprietary core platform – *Lm* Technology™ – alters a live, attenuated strain of *Listeria monocytogenes* (*Lm*) bacteria to stimulate cancer-fighting T-cells directed against cancer antigens and reduce factors that protect the tumor microenvironment from immunologic attack and contribute to tumor growth.

Advaxis' lead *Lm* Technology™ immunotherapies, axalimogene filolisbac and ADXS-DUAL, target HPV-associated cancers and are in clinical trials for four potential indications, including phase 3 in high risk, local advanced cervical cancer, a registrational quality study in metastatic cervical cancer in combination with nivolumab, phase 2 in head and neck cancer, and phase 2 in anal cancer. The FDA has granted axalimogene filolisbac orphan drug designation for three of these clinical settings, as well as Fast Track designation for adjuvant therapy for HRLACC patients and a SPA for the phase 3 AIM2CERV trial in HRLACC patients. Axalimogene filolisbac has also been classified as an advanced therapy medicinal product for the treatment of cervical cancer by the EMA's CAT.

Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development. In addition, Advaxis and Amgen are developing ADXS-NEO, an investigational cancer immunotherapy treatment designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor, with plans to enter the clinic in 2017.

Advaxis is developing more than 20 distinct immunotherapies directly or in partnership with recognized cancer centers of excellence and with support from advocacy foundations such as: the Radiology Therapy Oncology Group Foundation, the GOG Foundation, the Children's Oncology Group, Brown University Oncology Group, the Icahn School of Medicine at Mount Sinai, and others. In addition, Advaxis has embraced strategic collaborations with other major biopharmaceutical companies such as Amgen, Bristol Myers Squibb, Merck and others.

RECENT NEWS

Advaxis' Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017

Jun 26 2017, 8:55 AM EDT

MANAGEMENT TEAM

Daniel J. O'Connor, J.D.

President, Chief Executive Officer and Director

Robert G. Petit, Ph.D.

Executive Vice President and Chief Scientific Officer

Sara Bonstein, MBA

Executive Vice President and Chief Financial Officer

Anthony A. Lombardo

Executive Vice President and Chief Business Officer

Christopher Duke

Senior Vice President and Chief Operating Officer

Robert W. Ashworth, Ph.D.

Senior Vice President, Regulatory Affairs, Quality and Compliance

Thomas W. Hare

Senior Vice President, Product Development

Mayo Pujols

Senior Vice President, Technical Operations

Ranya Dajani

Vice President, Business Development

ADVAXIS, INC.

305 College Road East
Princeton, NJ 08540
US

STOCK OVERVIEW

Symbol	ADXS
Exchange	NASDAQ
Shares OS	40,462,700
Market Cap	\$266.65M
Last Price	\$6.59
52-Week Range	\$5.70 - \$16.30

INVESTOR RELATIONS

Advaxis, Inc.
Noelle Heber
Sr. Director, Corporate
Communications and Government
Affairs
305 College Rd East
Princeton, NJ 08540
T: 609-250-7575
F: 609-452-9818
heber@advaxis.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.